Accidental natalizumab administration to the third trimester of pregnancy in an adolescent patient with multiple sclerosis

Acta Neurologica Scandinavica

Volumn 124, Issue 4, 2011, Pages 290-292

  Bayas, A ^a   Penzien, J ^a   Hellwig, K ^b  

^a KLINIKUM AUGSBURG   (Germany)

^b ST JOSEF HOSPITAL   (Germany)

Author keywords

Multiple sclerosis; Natalizumab; Pregnancy

Indexed keywords

BETA1A INTERFERON; CORTICOSTEROID; DECONGESTIVE AGENT; FINGOLIMOD; GLATIRAMER; HYDROTALCITE; IBUPROFEN; IMMUNOGLOBULIN; NATALIZUMAB; PARACETAMOL;

ADOLESCENT; BLOOD CELL COUNT; BODY HEIGHT; BODY WEIGHT; BREAST FEEDING; CASE REPORT; CEREBELLUM; CIGARETTE SMOKING; DELIVERY; DISEASE EXACERBATION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG WITHDRAWAL; DYSPNEA; FEMALE; HEAD CIRCUMFERENCE; HEMIPARESIS; HUMAN; INFORMED CONSENT; LYMPHOCYTE COUNT; MOTOR PERFORMANCE; MULTIPLE SCLEROSIS; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; PREGNANCY OUTCOME; PRENATAL DEVELOPMENT; RELAPSE; REMISSION; THIRD TRIMESTER PREGNANCY; VERTIGO;

ADOLESCENT; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; FETAL DEVELOPMENT; HUMANS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PREGNANCY TRIMESTER, THIRD; TREATMENT OUTCOME;

EID: 80053051106     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2010.01480.x     Document Type: Note

References (17)

1. Simone IL, Carrara D, Tortorella C et al. Course and prognosis in early-onset MS: comparison with adult-onset forms. Neurology 2002;59:1922-8.
2. Bennett JL, Stuve O. Update on inflammation, neurodegeneration, and immunoregulation in multiple sclerosis: therapeutic implications. Clin Neuropharmacol 2009;32:121-32.
3. Pohl D, Waubant E, Banwell B et al. Treatment of pediatric multiple sclerosis and variants. Neurology 2007;68:S54-65.
4. Polman CH, O'connor PW, Havrdova E et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Eng J Med 2006;354:899-910.
5. Rudick RA, Stuart WH, Calabresi PA et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Eng J Med 2006;354:911-23.
6. Brown BA. Natalizumab in the treatment of multiple sclerosis. Ther Clin Risk Manag 2009;5:585-94.
7. Putzki N, Yaldizli O, Maurer M et al. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries. Eur J Neurol 2010; 17: 31-7.
8. Wehner NG, Shopp G, Osterburg I, Fuchs A, Buse E, Clarke J. Postnatal development in cynomolgus monkeys following prenatal exposure to natalizumab, an alpha4 integrin inhibitor. Birth Defects Res 2009;86:144-56.
9. Ghezzi A, Pozzilli C, Grimaldi LM et al. Safety and efficacy of natalizumab in children with multiple sclerosis. Neurology 2010;75:912-7.
10. Borriello G, Prosperini L, Luchetti A, Pozzilli C. Natalizumab treatment in pediatric multiple sclerosis: a case report. Eur J Paediatr Neurol 2009;13:67-71.
11. Huppke P, Stark W, Zurcher C, Huppke B, Bruck W, Gartner J. Natalizumab use in pediatric multiple sclerosis. Arch Neurol 2008;65:1655-8.
12. Polman CH, Reingold SC, Edan G et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005;58:840-6.
13. Krupp LB, Banwell B, Tenembaum S. Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology 2007;68:S7-12.
14. Elovaara I, Hietaharju A. Can we face the challenge of expanding use of intravenous immunoglobulin in neurology? Acta Neurol Scand 2010;122:309-15.
15. Wehner NG, Shopp G, Rocca MS, Clarke J. Effects of natalizumab, an alpha4 integrin inhibitor, on the development of Hartley guinea pigs. Birth Defects Res 2009;86:98-107.
16. Wehner NG, Shopp G, Oneda S, Clarke J. Embryo/fetal development in cynomolgus monkeys exposed to natalizumab, an alpha4 integrin inhibitor. Birth Defects Res 2009;86:117-30.
17. Hellwig K, Brune N, Haghikia A et al. Reproductive counselling, treatment and course of pregnancy in 73 German MS patients. Acta Neurol Scand 2008;118:24-8.